Spotlight On... SRI pairs with Stanford on discovery project; Aptuit invests in early R&D; and much more...

SRI International's in-house CRO has teamed up with Stanford University to find some early-stage treatments for cancer and push them through preclinical development. Under what has been dubbed the SRI Biosciences-Stanford Drug Discovery and Development Program, the two institutions plan to pool their resources and expertise in hopes of hitting on first-in-class therapies for multiple forms of cancer. More

> Aptuit is investing $16 million in infrastructure and planning to hire about 90 scientists in Europe as it works to expand its share of the market for drug discovery services. News

> Evotec notched a milestone in its endometriosis-focused partnership with Bayer, advancing two projects toward clinical development. Item

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.